Double maintains 1 strategies that include FATE - Fate Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 52.53% | $944.78M | 0.75% |
GNOM | 50.03% | $40.65M | 0.5% |
XBI | 44.97% | $4.85B | 0.35% |
IWC | 43.22% | $766.88M | 0.6% |
PTH | 38.87% | $96.56M | 0.6% |
CPRJ | 38.22% | $48.43M | 0.69% |
IWM | 37.31% | $63.95B | 0.19% |
VTWO | 37.15% | $12.07B | 0.07% |
IWN | 37.03% | $11.10B | 0.24% |
IBB | 36.90% | $5.22B | 0.45% |
IWO | 36.21% | $11.36B | 0.24% |
PINK | 35.52% | $131.52M | 0.5% |
GSSC | 35.23% | $538.65M | 0.2% |
ARKK | 34.90% | $5.95B | 0.75% |
PBE | 34.47% | $214.12M | 0.58% |
KJUL | 34.39% | $113.35M | 0.79% |
SCHA | 34.14% | $16.91B | 0.04% |
PRFZ | 33.94% | $2.33B | 0.34% |
KJAN | 33.80% | $305.13M | 0.79% |
PSC | 33.38% | $811.78M | 0.38% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTLA | 55.24% | $836.43M | -69.14% | 0.00% |
ALLO | 55.02% | $238.42M | -63.79% | 0.00% |
CRSP | 53.03% | $3.14B | -34.78% | 0.00% |
CRBU | 52.15% | $78.11M | -76.60% | 0.00% |
RXRX | 49.90% | $1.73B | -55.31% | 0.00% |
RCKT | 49.33% | $724.54M | -71.26% | 0.00% |
BEAM | 49.24% | $1.73B | -27.49% | 0.00% |
IMNM | 47.03% | $696.10M | -44.44% | 0.00% |
YMAB | 47.02% | $174.80M | -67.43% | 0.00% |
ABCL | 45.03% | $602.94M | -46.56% | 0.00% |
RGNX | 44.27% | $433.39M | -46.03% | 0.00% |
CGEM | 43.86% | $427.27M | -69.59% | 0.00% |
ARWR | 43.65% | $2.12B | -38.64% | 0.00% |
VRDN | 42.79% | $1.03B | -13.74% | 0.00% |
KYMR | 42.38% | $1.95B | -15.67% | 0.00% |
KALV | 42.29% | $579.68M | -3.40% | 0.00% |
EDIT | 42.04% | $116.78M | -76.32% | 0.00% |
IGMS | 42.04% | $69.13M | -87.62% | 0.00% |
KURA | 41.39% | $515.12M | -74.11% | 0.00% |
IDYA | 41.32% | $1.52B | -58.32% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FATBB | -0.01% | $50.77M | -11.65% | 9.83% |
HRTG | -0.02% | $742.60M | +160.15% | 0.00% |
CHRW | 0.03% | $11.72B | +18.76% | 2.46% |
GLP | -0.03% | $1.71B | +15.84% | 5.85% |
ARMK | -0.03% | $10.05B | +14.32% | 1.07% |
KOF | -0.04% | $4.80B | -6.62% | 4.51% |
BTU | -0.05% | $1.74B | -36.57% | 2.62% |
GSHD | 0.05% | $2.73B | +81.29% | 0.00% |
SUZ | 0.06% | $11.77B | -2.77% | 0.00% |
CNA | -0.06% | $13.19B | +12.80% | 3.67% |
TSLX | 0.07% | - | - | 8.97% |
PEG | 0.07% | $39.14B | +5.69% | 3.09% |
UGP | -0.07% | $3.30B | -37.47% | 4.06% |
WM | -0.09% | $91.76B | +7.46% | 1.35% |
AIZ | -0.10% | $10.11B | +13.68% | 1.53% |
MMC | 0.11% | $111.97B | +8.65% | 1.43% |
HPK | 0.11% | $1.25B | -31.68% | 1.63% |
NEE | -0.15% | $153.47B | -2.43% | 2.84% |
LQDT | -0.15% | $769.90M | +25.50% | 0.00% |
LMT | -0.18% | $108.98B | +0.07% | 2.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KMB | -13.98% | $45.57B | +1.99% | 3.58% |
BULL | -13.64% | $5.67B | +11.22% | 0.00% |
NOC | -13.62% | $67.51B | -0.35% | 1.76% |
CBOE | -12.26% | $22.95B | +20.67% | 1.12% |
K | -12.16% | $28.49B | +32.17% | 2.77% |
CME | -11.66% | $98.74B | +28.80% | 3.84% |
CTRE | -10.74% | $5.49B | +15.16% | 4.19% |
CHD | -10.09% | $23.29B | -11.36% | 1.23% |
INGR | -9.41% | $8.93B | +16.83% | 2.30% |
VHC | -9.34% | $34.69M | +74.89% | 0.00% |
EQNR | -8.90% | $64.45B | -12.15% | 5.91% |
TEF | -8.79% | $27.20B | +8.80% | 6.44% |
ENIC | -8.17% | $5.46B | +25.00% | 0.00% |
KR | -8.00% | $44.68B | +24.17% | 1.89% |
ABEV | -7.79% | $39.74B | +6.28% | 4.29% |
CQP | -7.39% | $29.63B | +27.28% | 5.30% |
OHI | -7.30% | $10.52B | +18.48% | 7.38% |
PSQH | -7.10% | $89.26M | -49.87% | 0.00% |
PG | -6.42% | $380.78B | -3.25% | 2.51% |
CCU | -6.20% | $2.62B | +5.98% | 3.17% |
Yahoo
Fate Therapeutics ( NASDAQ:FATE ) First Quarter 2025 Results Key Financial Results Revenue: US$1.63m (down 15% from 1Q...
Yahoo
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Yahoo
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 17.95% and 222.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine Advanced Therapy Designation Granted by the FDA for FT819 in Moderate-to-Severe Systemic Lupus Erythematosus Expanding FT819 Phase 1 Study to Include Treatment of Multiple Additional B Cell-mediated Autoimmune Diseases and Ex-US Territories $273 Million in Cash, Cash Equivalents, an
Finnhub
SAN DIEGO — SAN DIEGO — Fate Therapeutics Inc. on Tuesday reported a loss of $37.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 32...
SeekingAlpha
Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or sector-wide trends. Click here to read.
Current Value
$1.001 Year Return
Current Value
$1.001 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.10% | $361.41M | 1.43% |
VIXY | -21.30% | $109.64M | 0.85% |
CTA | -18.08% | $1.05B | 0.76% |
SHYD | -16.50% | $318.05M | 0.35% |
DFNM | -14.21% | $1.53B | 0.17% |
VRIG | -13.24% | $1.19B | 0.3% |
TAIL | -12.59% | $140.49M | 0.59% |
BSMW | -12.45% | $102.62M | 0.18% |
BSMR | -12.40% | $245.57M | 0.18% |
AGZD | -12.01% | $127.42M | 0.23% |
FMHI | -11.29% | $757.44M | 0.7% |
MLN | -10.83% | $532.71M | 0.24% |
SMB | -10.23% | $269.10M | 0.07% |
DBE | -10.14% | $48.48M | 0.77% |
PWZ | -9.96% | $671.52M | 0.28% |
SHYM | -9.85% | $322.93M | 0.35% |
TAXF | -9.26% | $500.81M | 0.29% |
PZA | -9.09% | $2.89B | 0.28% |
ITM | -8.94% | $1.97B | 0.18% |
IBMO | -8.52% | $512.46M | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLTR | 0.01% | $2.37B | 0.14% |
VGIT | -0.06% | $31.33B | 0.04% |
AGZ | 0.08% | $607.46M | 0.2% |
UTWO | -0.10% | $387.71M | 0.15% |
BOND | -0.12% | $5.46B | 0.7% |
IBTL | -0.13% | $367.56M | 0.07% |
UDN | -0.16% | $137.74M | 0.78% |
CLIP | 0.18% | $1.50B | 0.07% |
CGCB | -0.20% | $2.19B | 0.27% |
SMMU | 0.20% | $822.53M | 0.35% |
UTEN | -0.21% | $192.72M | 0.15% |
BSCT | 0.24% | $1.98B | 0.1% |
IEI | 0.25% | $16.09B | 0.15% |
VCSH | 0.27% | $34.94B | 0.03% |
USDU | 0.28% | $173.44M | 0.5% |
GOVI | 0.29% | $870.08M | 0.15% |
BILZ | -0.29% | $876.85M | 0.14% |
BIL | 0.32% | $45.95B | 0.1356% |
IBDU | 0.32% | $2.54B | 0.1% |
KBA | -0.38% | $175.37M | 0.56% |